Ranolazine attenuates behavioral signs of neuropathic pain.

Abstract

Ranolazine modulates the cardiac voltage-gated sodium channel (NaV 1.5) and is approved by the FDA in the treatment of ischemic heart disease. Ranolazine also targets neuronal (NaV 1.7, 1.8) isoforms that are implicated in neuropathic pain. Therefore, we determined the analgesic efficacy of ranolazine in a preclinical animal model of neuropathic pain. Both intraperitoneal and oral administration of ranolazine dose-dependently inhibited the mechanical and cold allodynia associated with spared nerve injury, without producing ataxia or other behavioral side effects. These data warrant clinical investigation of the potential use of ranolazine in the treatment of neuropathic pain.

• Authors: Harry J Gould 3rd, Colleen Garrett, Renee R Donahue, Dennis Paul, Ivan Diamond, Bradley K Taylor
• Journal: Behavioural pharmacology (Behav Pharmacol) Vol. 20 Issue 8 Pg. 755-8 (Dec 2009) ISSN: 1473-5849 [Electronic] England
• PMID: 19773645 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)

Chemical References

• Acetanilides
• Piperazines
• Sodium Channel Blockers
• Ranolazine

Topics

• Acetanilides (administration & dosage, pharmacology, therapeutic use)
• Animals
• Ataxia (chemically induced)
• Behavior, Animal (drug effects)
• Cold Temperature
• Drug Evaluation, Preclinical
• Injections, Intraperitoneal
• Injections, Subcutaneous
• Male
• Nervous System Diseases (drug therapy, physiopathology)
• Neuralgia (drug therapy)
• Pain Measurement
• Pain Threshold (drug effects)
• Physical Stimulation
• Piperazines (administration & dosage, pharmacology, therapeutic use)
• Random Allocation
• Ranolazine
• Rats
• Rats, Sprague-Dawley
• Reaction Time (drug effects)
• Sodium Channel Blockers (administration & dosage, pharmacology, therapeutic use)